Dogwood Therapeutics Inc (DWTX): DWTX future is looking very bright&#x1F6...

DavidLeeRoth · 2026-03-03T14:21:53.6600000Z

DWTX future is looking very bright😎💰 https://x.com/dogwoodther/status/2028837725168935231?s=61

Prev Next

Send PM Follow Ignore

Followers	205
Posts	15015
Boards Moderated	3
Alias Born	04/03/2007

DavidLeeRoth

Re: None

Tuesday, 03/03/2026 9:21:53 AM

Tuesday, March 03, 2026 9:21:53 AM

DWTX future is looking very bright😎💰

$DWTX's Halneuron has shown statistically & clinically reduced pain in cancer-related pain & CINP #clinicaltrials, respectively. General cancer pain responders exhibited long-lasting relief & no evidence of addiction or tolerance in prior #clinicaltrials.https://t.co/2wkAfepxIr pic.twitter.com/SEtNnjnFxn
— Dogwood Therapeutics (@DogwoodTher) March 3, 2026

Bullish

Keep Last Read

Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent DWTX News

Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 01:00:12 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/18/2026 08:30:36 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2026 01:00:22 PM
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:30:18 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:20:01 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:16:38 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/13/2026 09:05:34 PM
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 • GlobeNewswire Inc. • 02/02/2026 01:30:00 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/30/2026 05:15:21 AM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/23/2026 09:30:09 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 01:30:09 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/15/2026 09:19:51 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 05:38:14 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/13/2026 05:06:04 PM
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development • GlobeNewswire Inc. • 01/12/2026 01:30:00 PM
Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/08/2026 09:10:38 PM
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain • GlobeNewswire Inc. • 12/22/2025 03:15:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 09:05:15 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 09:05:12 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 09:05:10 PM
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 • ACCESS Newswire • 12/02/2025 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2025 07:15:10 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/28/2025 07:00:50 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent DWTX News

More DWTX News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent DWTX News

Go Ad-Free